Your browser doesn't support javascript.
loading
Nasal IL-13 production identifies patients with late-phase allergic responses.
Campion, Nicholas J; Villazala-Merino, Sergio; Thwaites, Ryan S; Stanek, Victoria; Killick, Helen; Pertsinidou, Eleftheria; Zghaebi, Mohammed; Toth, Josef; Fröschl, Renate; Perkmann, Thomas; Gangl, Katharina; Schneider, Sven; Ristl, Robin; Scott, Ian C; Cohen, Emma Suzanne; Molin, Magnus; Focke-Tejkl, Margit; Regelsberger, Guenther; Hansel, Trevor T; Valenta, Rudolf; Niederberger-Leppin, Verena; Eckl-Dorna, Julia.
Affiliation
  • Campion NJ; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Villazala-Merino S; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Thwaites RS; National Heart and Lung Institute, Imperial College of London, London, United Kingdom.
  • Stanek V; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Killick H; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Pertsinidou E; Research and Development, Thermo Fisher Scientific, Uppsala, Sweden.
  • Zghaebi M; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Toth J; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Fröschl R; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Perkmann T; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Gangl K; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Schneider S; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
  • Ristl R; Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
  • Scott IC; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Cohen ES; Bioscience Asthma, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Molin M; Research and Development, Thermo Fisher Scientific, Uppsala, Sweden.
  • Focke-Tejkl M; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria; Karl Landsteiner University of Health Sciences, Krems, Austria.
  • Regelsberger G; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria.
  • Hansel TT; National Heart and Lung Institute, Imperial College of London, London, United Kingdom.
  • Valenta R; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria; Karl Landsteiner University of Health Sciences, Krems, Austria.
  • Niederberger-Leppin V; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria. Electronic address: verena.niederberger@meduniwien.ac.at.
  • Eckl-Dorna J; Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria.
J Allergy Clin Immunol ; 152(5): 1167-1178.e12, 2023 11.
Article de En | MEDLINE | ID: mdl-37536510
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Rhinite allergique saisonnière / Hypersensibilité Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans Langue: En Journal: J Allergy Clin Immunol Année: 2023 Type de document: Article Pays d'affiliation: Autriche Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Rhinite allergique saisonnière / Hypersensibilité Type d'étude: Clinical_trials / Prognostic_studies Limites: Humans Langue: En Journal: J Allergy Clin Immunol Année: 2023 Type de document: Article Pays d'affiliation: Autriche Pays de publication: États-Unis d'Amérique